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Macrolide resistance in Staphylococcus aureus
involves two mechanisms. The first mechanism is
known as the MLSB phenotype and is encoded by the
erm gene (A, B, C) which results in target site
modification through methylation of the adenine
residue of bacterial 23S ribosomal RNA, conferring
resistance not only to macrolides (erythromycin),
but also to lincosamides (clindamycin) and strepto-
gramin-B (MLS) antibiotics.1 This phenotype can be
expressed either constitutively, which means the
isolate is resistant to all MLS antibiotics, or it can
be inducible which can be detected by the D test.2
The second mechanism is through the efflux pump
encoded by themsr A gene which confers resistance
to the macrolides and type B streptogramins only.3
In vitro, the staphylococci carrying the erythromy-
cin-inducible resistance are resistant to macrolides
(erythromycin) but are susceptible to clindamycin.
However, following exposure to clindamycin in vivo,
they can mutate to constitutive resistance thus
becoming resistant to MLS antibiotics. To document
this resistance pattern among S. aureus in vitro, a
preliminary study was undertaken in the Depart-
ment of Microbiology, PES Institute of Medical
Sciences and Research, a 530-bed tertiary care
center.
Between January and June 2004, a total of 120
isolates of S. aureus from various clinical specimens
from hospitalized patients (one isolate per patient)
were identified by standard methods.4 Antibiotic
susceptibility tests were performed by Kirby—Bauer
disk diffusion.5 Methicillin-resistant S. aureus
(MRSA) screening was done by the oxacillin (1 mg)
disk diffusion method.6 Inducible clindamycin
resistance was detected by the D test2 on Muel-
ler—Hinton Agar. Briefly, clindamycin (2 mg) and
erythromycin (15 mg) disks were placed 15—
20 mm apart along with other antibiotic disks onTable Erythromycin (ERY) and clindamycin (CLI) susceptib
S. aureus N ERY res + CLI sen
D test + D te
MRSA 42 (35) 8 (19) 10 (2
MSSA 78 (65) 15 (19.2) 20 (2
Total 120 23 (19.1) 30 (2
MRSA: Methicillin-resistant S. aureus; MSSA: Methicillin-sensitive
inducible CLI res; D test —: absence of inducible CLI res. Numbersa routine antibiotic susceptibility testing plate and
incubated at 37 8C overnight. S. aureus ATCC 25923
was used for quality control of antibiotic disks and
as a control strain showing no inducible resistance.
A zone around the clindamycin disk that is flattened
(D shaped) on the side next to the erythromycin disk
(inducer) indicated the presence of inducible resis-
tance; no flattening indicated absence of inducible
resistance. Constitutively resistant strains grow up
to both disks. The panel of antibiotic disks (mg) used
was as follows: penicillin (10 units), erythromycin
(15), clindamycin (2), oxacillin (1), gentamicin
(10), amikacin (30), ciprofloxacin (5), trimetho-
prim—sulfamethoxazole (25), rifampin (5), vanco-
mycin (30), linezolid (30), amoxicillin—clavulanic
acid (30).
Of 120 S. aureus isolates, 35% were MRSA; 65%
were methicillin-sensitive S. aureus (MSSA); 19.1%
revealed the presence (D test positive) and 25%
revealed the absence (D test negative) of inducible
clindamycin resistance and 30.8% were constitu-
tively resistant (Table). No significant differences
in the presence (19% in MRSA and 19.2% in MSSA) and
absence (23.8% in MRSA and 25.6% in MSSA) of
inducible clindamycin resistance between MRSA
and MSSAwere seen (Table). Constitutive resistance
in MRSA was 57.1% whereas it was 16.6% in MSSA.
Thirty (38.4%) MSSA isolates were sensitive to both
erythromycin and clindamycin whereas none of the
MRSA was sensitive to both. Twenty-five percent of
S. aureus (23.8% MRSA and 25.6% MSSA) were ery-
thromycin-resistant, clindamycin-susceptible and D
test negative (Table). Overall resistance to rifampi-
cin, amikacin, ciprofloxacin, trimethoprim—sulfa-
methoxazole and penicillin among S. aureus was
10%, 16.6%, 33.3%, 56.6% and 86.6% respectively.
No resistance was observed to vancomycin and line-
zolid.
Clindamycin is often effective for the treatment
of community-acquired MRSA infections, but should
be restricted to those strains with macrolide resis-
tance mediated by efflux and not by methylating
enzymes.7,8 Otherwise, treatment of inducible MLS-ility patterns in MRSA and MSSA.
ERY res + CLI res ERY sen + CLI sen
st 
3.8) 24 (57.1) 0
5.6) 13 (16.6) 30 (38.4)
5) 37 (30.8) 30 (25)
S. aureus; res: resistant;, sen: sensitive; D test +: presence of
in parentheses indicate percentages.
Letters to the Editor 185resistant S. aureus isolates with clindamycin may
lead to clinical failure.8,9 In the present study, 19.1%
of S. aureus (19% in MRSA and 19.2% in MSSA) were
inducible clindamycin-resistant. A similar type of
study in two different hospitals in Chicago, USA
revealed 7% and 12% inducible clindamycin resis-
tance for MRSA and MSSA respectively.10 However
there are no data currently available to compare the
results in India. In addition, 25% of S. aureus isolates
(23.8% in MRSA and 25.6% in MSSA) were erythro-
mycin-resistant, clindamycin-susceptible and D test
negative, probably indicating an efflux pump
mediated mechanism (non-inducible) that needs
further study. This is a preliminary report; further
studies and follow-up on larger numbers of isolates
have to be undertaken to determine the relationship
between methicillin and macrolide resistance
among S. aureus. Performing the D test on a routine
antibiotic susceptibility plate would detect the
inducible clindamycin resistance early in S. aureus.
In addition, it also provides the possible status of
non-inducible isolates where clindamycin may be an
important therapeutic option.7—9
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Three major device-associated hospital-
acquired infections were selected for analysis:
urinary tract infection (UTI), ventilator-associated
pneumonia (VAP), and catheter-associated blood-
stream infection (BSI). Data from 478 patients
undergoing cardiac surgery and admitted to the
ICU during the period 1 March 2000 to 31 August
2000 were prospectively collected and analyzed.
A total of 4.1 device-associated infections per 1000
patient-days were documented; individual infec-
tion rates and device utilization rates are shown in
Tables 1 and 2.
